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Abstract: Congenital heart disease is one of the major diagnoses in pediatric heart transplantation recipients of all age 
groups. Assessment of pulmonary vascular resistance in these patients prior to transplantation is crucial to determine their 
candidacy, however, it is frequently inaccurate because of their abnormal anatomy and physiology. This problem places 
them at significant risk for pulmonary hypertension and right ventricular failure post transplantation. The pathophysiology 
of pulmonary vascular disease in children with congenital heart disease depends on their pulmonary blood flow patterns, 
systemic ventricle function, as well as semilunar valves and atrioventricular valves structure and function. In our review 
we analyze the pathophysiology of pulmonary vascular disease in children with congenital heart disease and end-stage 
heart failure, and outline the state of the art pre-transplantation medical and surgical management to achieve reverse re-
modeling of the pulmonary vasculature by using pulmonary vasodilators and mechanical circulatory support.  
Keywords: Congenital heart disease, pulmonary vascular resistance, heart transplantation. 
INTRUDCTION 
Heart transplantation (HT) is increasingly considered a 
treatment option for patients with congenital heart disease 
(CHD) and end-stage heart failure. According to the registry 
of the International Society of Heart and Lung Transplanta-
tion, 63% of infant heart recipients, and 25% of heart recipi-
ents aged 11 to 17 years between January 1996 and June 
2009, carry the underlying diagnosis of CHD [1]. A recent 
analysis of the Pediatric heart Transplant Study registry [2] 
identified 488 children (6 months-18 years of age) with CHD 
at the time of listing for HT transplanted at 35 centers from 
January 1990 through December 2002. Patients<6 months of 
age were excluded from analysis due to differing listing al-
gorithms in United States. The major diagnostic categories 
for the 488 study patients were single ventricle (36%), d-
transposition of the great arteries (12%), right ventricular 
outflow tract lesions (most commonly Tetralogy of Fallot) 
(10%), ventricular/atrial septal defect (8%), l-transposition of 
the great arteries (8%), and complete atrioventricular canal 
defect (8%). 454 of patients had at least 1 operation before 
HT. Staged palliation for single ventricle, including the 
Norwood procedure, or variants of the Glenn procedure, was 
the last operation in approximately 20% of the patients, and 
the Fontan operation was the last surgical procedure in 107 
patients, representing 22% of the CHD population.  
  Congenital diagnosis remains a highly significant risk 
factor for mortality one and five years after HT [1]. Accurate 
listing of patients for HT requires assessment of the pulmo-
nary vascular resistance (PVR) to avoid the potential of   
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donor right heart failure [3, 4] Unfortunately, despite ad-
vances in perioperative management and careful preselec-
tion, pulmonary hypertension related right ventricular failure 
still occurs in pediatric HT recipients [5]. 
  In patients with CHD, given the high post HT mortality 
risk, accurate assessment of PVR has increased importance, 
but paradoxically, these patients are often harder to assess. 
Anomalies within the pulmonary vasculature or dual sup-
plies of pulmonary blood flow may make accurate calcula-
tions of resistance impossible. The sluggish pulmonary and 
hepatic blood flow in the Fontan circuit increases the risk for 
microemboli and arteriovenous malformations that may 
change the distribution of blood flow to the right and left 
lung. The assumption that elevated PVR may contribute to 
late Fontan failure even in patients with “normal” pre-HT 
PVR was studied by Mitchell and colleagues [6]. This group 
conducted a single center retrospective study of patients who 
underwent HT for failing Fontan and Kawashima circula-
tions and compared pre- and post- HT cardiac catheterization 
pulmonary hemodynamics. They found post HT elevation of 
transpulmonary gradient (TPG) and PVR in all patients with 
late Fontan circulation failure (range 10-16 mmHg and 2.8-
5.4 Wood units •
 m
2, respectively) and concluded that “the 
increase in TPG and PVR to pathologic levels post HT re-
flects a fixed element of PVR that was unmasked with the 
introduction of normal pulmonary blood flow”.  
  The risk of post HT right ventricular failure and mortality 
in children with heart disease and elevated PVR is well es-
tablished and underlines the need for pre-transplantation 
assessment of TPG and PVR. The same experience in adults 
led to recommendations that HT should not be performed if 
the PVR index exceeds 6 Wood units •
 m
2 or if the TPG is 
greater than 15 mmHg. However, these recommendations do 
not take into account possible reversibility of elevated PVR. 60    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Gazit and Canter 
In fact, partial or complete reversibility of elevated PVR and 
TPG were observed acutely in response to short acting sys-
temic and pulmonary vasodilators such as nitroprusside [7], 
prostaglandin E1 [8], and inhaled nitric oxide [9, 10], and in 
response to prolonged administration of a phosphodiesterase-
5 inhibitor such as sildenafil [11-13], endothelin antagonist 
such as bosentan [14], and inotropic agents such as milrinone 
[15] dopamine and dobutamine [16]. Based on available re-
ports, children who demonstrate PVR reversibility can suc-
cessfully undergo orthotopic HT even if their PVR index 
exceeds 6 Wood units •
 m
2 or if the TPG exceeds 15 mmHg 
(see discussion below: Hemodynamic unloading and regres-
sion of fixed pulmonary vascular resistance). 
PATHOPHYSIOLOGY AND NATURAL HISTORY 
(1) Effects of shear stress on the vascular endothelium 
  As blood flows through a vessel it exerts a physical force 
on the vessel wall. This force generates stress that can be 
resolved into two principal vectors. [1] The stress parallel to 
the vessel wall is defined as shear stress. This represents the 
frictional force that blood flow exerts on the endothelial sur-
face of the vessel wall. [2] The stress perpendicular to the 
vessel wall is defined as tensile stress. This represents the 
dilating force of blood pressure on the vessel wall.  
  The absolute shear stress varies throughout the cardiac 
cycle because of its pulsatile nature. In regions where stable 
flow is unidirectional with no recirculation, the time-
averaged fluctuations in shear stress are positive (forward 
flow). Such laminar flow is known as mean positive shear 
stress. Temporal shear-stress gradients are defined as the 
increase or decrease of shear stress over a small period of 
time at the same location. Spatial shear-stress gradients are 
defined as the difference of shear stress between two close 
points of an endothelial cell at the same point in time. Mean 
positive shear stress greater than 6 dyne/cm
2 predominates 
throughout much of the major systemic arterial vasculature. 
Recirculating flow occurs mainly around branch points and 
distal to areas of stenosis. The interaction between the 
hemodynamic forces generated by this flow and the systemic 
vascular endothelium may cause local formation of athero-
sclerotic lesions. It is important to note that the flow profiles 
within recirculation zones should not be confused with tur-
bulent flow, since turbulence implies random movement of 
elements in the flow field. Turbulent flow accounts for a 
very small fraction of the total systemic flow.  
  The morphology of endothelial cells within regions of 
recirculating flow is significantly different from cells located 
within regions of mean positive shear stress [17, 18]. Cells in 
these regions are not aligned and are characterized by a 
rounded shape, an increased proliferation rate and increased 
permeability [19-22]. Endothelial cells located within re-
gions of mean positive shear stress are aligned with their 
longitudinal axis parallel to the direction of blood flow [17, 
18]. This orientation effectively decreases drag resistance 
[23]. Based on these physiological observations it appears 
that mean positive shear stress acts as an endothelial cell 
survival factor rather than a growth factor [24].  
  Based on studies characterizing the force-transduction 
pathways [25-41]. White and Frangos [42] hypothesize that 
“hydrodynamic shear destabilizes the plasma membrane, 
leading to…… an increase in membrane free volume. 
Changes in membrane microviscosity directly activate vari-
ous secondary signal cascades linked to heterotrimeric G 
protein. Tension generated across the cell membrane by fluid 
shear stress is transmitted to the cell-cell junction where 
known shear-sensitive proteins are localized. Furthermore, 
endothelial cell differentiation between mean positive shear 
stress and temporal gradients in shear stress takes place pri-
marily in the cell-cell junction and is dictated by the rate of 
tension generated between the two flow profiles.” 
(2) Pulmonary vascular remodeling: effects of pathologi-
cal pulmonary blood flow on pulmonary vascular struc-
ture. 
  Studies in animals and humans performed in the current 
era support the causal relationship between pathological 
pulmonary blood flow and the development of pulmonary 
hypertension [43-45]. The main mechanisms that may in-
crease PVR in children with heart disease are left atrial hy-
pertension due to systemic ventricular dysfunction, anatomic 
obstruction to pulmonary venous return, pulmonary veno-
occlusive disease, pulmonary arteriolar constriction, anat-
omic obstruction of the large pulmonary arteries, increased 
pulmonary blood flow in CHD with left to right shunting, 
accessory sources of pulmonary blood flow from aortopul-
monary collaterals, and sluggish pulmonary blood flow in 
children with single ventricle physiology following the Fon-
tan procedure. 
  In animals, both increased [46], and decreased flow [47] 
may induce adverse responses in the pulmonary vasculature. 
The effects of both pathologically high and low shear, com-
pared to physiological shear, on pulmonary endothelial pro-
duction of vasodilating and vasoconstricting factors were 
investigated by Li and colleagues [48] using monolayers of 
bovine pulmonary arterial endothelial cells and pulmonary 
arterial smooth muscle cells exposed to varying shear condi-
tions. They found that pathologically high and low flow at-
tenuated endothelial release of nitric oxide and prostaglandin 
F1a, and enhanced release of endothelin-1. A mediator pro-
duction profile that favors vasoconstriction.  
  In patients with congestive heart failure (CHF), persistent 
elevation of left-ventricular end-diastolic pressure causes 
passive pulmonary venous congestion and reactive pulmo-
nary vasoconstriction. At this preliminary stage, PVR is 
readily reversible with pulmonary vasodilators. However, 
persistent pulmonary venous congestion causes remodeling 
of the pulmonary arterial wall due to abnormalities of the 
elastic fibers, intimal fibrosis and medial hypertrophy. Pul-
monary hypertension secondary to structural remodeling is 
referred as fixed because it is resistant to pharmacological 
treatments. Delgado and colleagues [49] studied the pulmo-
nary vascular morphology of 17 adult HT recipients with 
preoperative CHF associated with ischemic heart disease, 
idiopathic dilated cardiomyopathy, valvular heart disease and 
constrictive pericarditis who died shortly after transplanta-
tion. Their main pathologic finding was medial hypertrophy 
of muscular pulmonary arteries.  
  In an older era, Rabinovitch and colleagues [50] per-
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from 50 patients, mostly under 2 years of age (range 2 days-
30 years) who underwent repair of ventricular septal defect, 
d-transposition of the great arteries, and atrioventricular ca-
nal. The findings were correlated with hemodynamic data 
obtained both pre and postoperatively. Three structural 
changes were observed and graded A, B, and C based on 
their severity (Table 1). A similar study performed by the 
same group at the Children’s Medical Center, Boston (July 
1976 to January 1981) [51] included performance of a lung 
biopsy at the time of the surgical repair on 74 patients with 
CHD who either had pulmonary hypertension or in whom it 
would be likely to develop if the lesion was not corrected. 
Structural changes were assessed based on the grading sys-
tem described above and also according to the classification 
of Heath and Edwards [52] (Table 1). Patients whose preop-
erative PVR was markedly elevated underwent biopsy first. 
If their pulmonary Heath-Edwards grade was IV to VI they 
were excluded from definitive repair. For the other patients, 
morphometric findings and Heath-Edwards grading were 
correlated with hemodynamic data from a cardiac catheteri-
zation performed immediately after surgery and about 1 year 
after surgery. Normal mean pulmonary pressure was taken as 
18 mmHg or less and normal PVR index as less than 3.5 
Wood units •
 m
2. The Heath-Edwards grading system was 
predictive of pulmonary hypertension in the early but not 
late post-operative period. The study findings suggested, at 
least for patients undergoing an operation in the first 2 years 
of life, that even severe intimal change (Heath-Edwards 
grade III) is not prognostic of persistent elevation in PVR if 
growth and development of the pulmonary arteries has been 
relatively normal (morphometric grade A or B (mild)). Pa-
tients who underwent surgical correction in the first 8 
months of life had normal pulmonary hemodynamics 1 year 
after repair despite marked structural abnormalities at the 
time of repair. Some of the patients operated on at 9 months 
of age that had pulmonary structural abnormalities as severe 
as in those operated on earlier had persistent elevation of 
PVR. Possible mechanisms are less complete regression of 
the abnormal findings, limited potential for growth of new 
normal vessels, or both. In patients with left to right shunt 
pulmonary vascular muscularization is accelerated, possibly 
because of mechanical or humoral growth stimulation gener-
ated by supra-physiological shear stress (see discussion of 
this term below) [53]. One possible cause of intimal hyper-
plasia in patients with CHD is endothelial over-regeneration 
in response to partial denudation of the endothelium of the 
more proximal intra-acinar arteries [54-56] . 
TREATMENT OPTIONS FOR PATIENTS WITH 
END-STAGE HEART FAILURE AND FIXED PVR 
Special Transplantation Techniques 
  Pulmonary hypertension is a risk factor for early and late 
mortality after heart transplantation. Gajarski and colleagues 
[57] studied the perioperative and intermediate outcomes in 
pediatric cardiac transplant recipients who had elevated PVR 
indexes preoperatively. They found that the vascular reactiv-
Table 1.  Grading of Pulmonary Vascular Pathology in Patients with CHD and Excessive Pulmonary Blood Flow. 
Morphometric 
Grade 
Heath-
Edwards 
Grade 
Morphometric Findings  Heath-Edwards Histopa-
thological Findings 
Pulmonary Hemo-
dynamic Profile 
A N  Extension of muscle into peripheral arteries normally 
nonmuscular, either as a solitary finding or associated with 
a mild increase in the medial wall thickness of the nor-
mally muscular arteries (1.5 normal). 
no striking evidence of medial 
hypertrophy, same as in the 
morphometric grade A  
B    Grade A findings with greater medial hypertrophy    
B (mild)  N  medial wall thickness is greater than 1.5 but less than 2 
times normal 
no striking evidence of medial 
hypertrophy, same as in the 
morphometric grade B(mild) 
Increased pulmonary 
blood flow without 
evidence of increased 
pulmonary artery 
pressure. 
B (severe)  I  wall thickness is 2 times normal.  medial hypertrophy can be 
appreciated subjectively as in 
morphometric grade B (severe) 
associated with pul-
monary arterial hy-
pertension. 
C   Grade B (severe) findings with a reduced number of pe-
ripheral arteries relative to alveoli and usually decreased 
arterial size 
 
C (mild)    more than half the normal number of arteries is present   
C (severe)    when half the normal number of arteries or less is present.   
 II    presence of eccentric or con-
centric intimal hyperplasia 
 III    occlusive intimal hyperplasia 
with hyalinization of the media 
Moderate-to-severe 
elevation in pulmo-
nary vascular resis-
tance 
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ity to pulmonary vasodilators and not the absolute PVR de-
termined orthotopic HT suitability, and that post-transplant 
donor right heart failure is unlikely if pre-transplant recipient 
PVR index was  4 Wood units •
 m
2 with vasodilator ther-
apy. Studies in adults revealed that mortality after HT is in-
creased if pharmacologic interventions are not able to reduce 
PVR below 2.5-3.5 Wood units •
 m
2 [58, 59] . A PVR that 
cannot be reduced below this threshold with pulmonary 
vasodilators is usually termed fixed PVR. Possible treatment 
options for patients with end-stage heart failure and fixed 
PVR are as follows:  
  [1] Heterotopic (“piggy back”) HT that allows preserva-
tion of the entire native heart. The latter provides assistance 
to the vulnerable transplanted right ventricle, however, the 
failing recipient left ventricle places the recipient at risk for 
lethal arrhythmias, systemic emboli, and compression of the 
left lung [60, 61]. 
  [2] Heart-lung transplantation. This procedure eliminates 
the diseased pulmonary vasculature, however, donors for 
heart-lung transplantation are rare, and the procedure has 
inherent long-term sequelae mainly related to its pulmonary 
component. 
  [3] Right ventricle-sparing heart transplant was attempted 
in a canine model [62, 63]. The aim of this procedure is to 
preserve the recipient's right ventricle, which is already con-
ditioned to pulmonary hypertension. 
  [4] Transplantation using hearts from donors with idio-
pathic pulmonary hypertension for recipients with high PVR 
(domino procedure). This is a viable but rare option in trans-
plant centers where patients undergo heart and lung trans-
plantation for idiopathic pulmonary hypertension [64].  
HEMODYNAMIC UNLOADING 
  A recent laboratory study performed by O’Blenes and 
colleagues [65], tested the hypothesis that hemodynamic 
unloading leads to regression of the structural changes asso-
ciated with obstructive pulmonary vascular disease. To do 
that they developed a model in which hypertensive rat lungs 
with experimental pulmonary vascular disease were hemo-
dynamically unloaded by transplantation into syngeneic, 
normotensive recipient rats. The initial stage of the experi-
ment included right middle and lower lobectomy and subse-
quent systemic injection of the toxin monocrotaline. With 
these interventions the investigators caused pulmonary vas-
cular disease to the remaining right upper lobe and left lung 
by increased blood flow combined with monocrotaline toxic 
endothelial injury. The second stage was performed 28 days 
following these interventions and included left lung harvest 
and transplantation. That procedure caused hemodynamic 
unloading of the transplanted lung since pulmonary blood 
flow was probably directed preferentially to the normal na-
tive lung (low resistance circuit). The findings were as fol-
lows: [1] Pulmonary artery pressures were normal 14 days 
after transplantation and only mildly elevated by day 28. [2] 
Right ventricle hypertrophy did not develop in the recipient 
animals. [3] Medial hypertrophy and peripheral musculariza-
tion improved. [4] Pulmonary artery density, although 
somewhat improved, remained markedly below baseline 
levels. 
  Following that experiment, hemodynamic unloading of 
patients with fixed pulmonary hypertension with pulsatile 
and nonpulsatile ventricular assist devices led to reduction of 
PVR and allowed listing for orthotopic HT after a relatively 
short period of support (3-6 months), Furthermore, survival 
of these patients after transplantation was comparable with 
that of patients without prior pulmonary hypertension [66-
77]. Based on our own experience [78], hemodynamic un-
loading with biventricular assist device combined with 
medical pulmonary vasodilator therapy leads to reversal of 
fixed pulmonary hypertension related to CHD. We have im-
planted Berlin Heart biventricular assist device (Berlin Heart 
AG, Berlin, Germany) in 13 patients from April 2005 to 
August 2008 [79] . The median age of the patients was 2 
years (12 days to 17 years). The etiology of heart failure was 
cardiomyopathy in 11 children and CHD in 2. In those 2 
patients with CHD, PVR index was greater than 10 Wood 
units •
  m
2 unresponsive to pulmonary vasodilator therapy. 
PVR index decreased to 1.4 and 4.6 Wood units •
 m
2 after 33 
and 41 days of support, respectively. Both patients under-
went orthotopic HT. Their PVR index remained normal 
without pulmonary vasodilator therapy within 3 months after 
transplantation. 
AT THE BEDSIDE: PRACTICAL CLINICAL AP-
PROACH 
Two-ventricle Physiology 
  A child with end-stage HF adequately treated with oral 
anti CHF medications who presents with acute decompen-
sated HF (ADHF) is admitted to the cardiac intensive care 
unit (CICU) for close non-invasive and invasive hemody-
namic monitoring. The initial treatment line for these pa-
tients is inotropic support. A recent review of the pharma-
ceutical management of decompensated heart failure syn-
drome in children discusses in detail the indications, mecha-
nism of actions, and dosages of the various available 
inotropes [80]. At St. Louis Children’s Hospital, the hemo-
dynamically unstable child is started on dopamine, dobu-
tamine or epinephrine as first line of inotropic treatment. If 
the child is stable hemodynamically, milrinone or dobu-
tamine are initiated. Following an initial stabilization period, 
a right heart cardiac catheterization is performed to delineate 
the TPG and PVR and determine the child’s candidacy for 
HT. Assessment of the hemodynamic profile with a pulmo-
nary artery (PA) catheter is an acceptable alternative in older 
children and allows titration of inotropic support to increase 
CO.  
Treatment Options Based on Different Possible Hemody-
namic Profiles 
1  Elevated but reactive PVR in the context of elevated LA 
pressure. First line of treatment is inotropic support 
combined with IV diuretics. The second treatment line is 
intubation and positive ventilation. The latter is a potent 
afterload reducing method by way of decreasing the left 
ventricular (LV) transmural pressure and hence wall 
tension. Intubation of a child with ADHF may cause 
acute hemodynamic collapse and cardiac arrest because 
of acute reduction of sympathetic tone with the preintu-
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dence of end-organ dysfunction and anaerobic metabo-
lism. The third line of treatment, if systemic perfusion 
remains inadequate is mechanical circulatory support. 
Treatment with pulmonary vasodilators in this subset of 
patients prior to initiation of MCS may be risky since it 
may worsen pulmonary edema. The decompression of 
the LV by a VAD in these patients is usually sufficient 
to decrease PVR, again with no need to treat with pul-
monary vasodilators. 
2  Fixed PVR in the context of LA hypertension. Treat-
ment of these patients is determined by their hemody-
namic status and systemic perfusion. Treatment is tar-
geted at optimization of CO. The combination of pul-
monary hypertension and LV failure usually results in 
inadequate systemic perfusion and shock because of 
ventricular interdependence and underlying LV systolic 
and diastolic dysfunction. These patients usually require 
aggressive cardiopulmonary support comprised of posi-
tive pressure ventilation, inotropic support, sedation and 
neuromuscular blockade. It is our opinion that pulmo-
nary vasodilators in this subset of patients are not bene-
ficial. Reverse remodeling of the pulmonary vasculature 
requires lowering the LVEDP. Achieving that with 
inotropic support and mechanical ventilation is ques-
tionable and may not be sustainable. Other considera-
tions are the debilitation and muscle degeneration that 
develops during prolonged mechanical ventilation and 
prolonged use of neuromuscular blockade. Based on our 
experience reverse remodeling of the pulmonary vascu-
lature using mechanical circulatory support can be 
achieved in children with CHD, and therefore, in this 
particular group of patients, we recommend early VAD 
implantation. 
SINGLE-VENTRICLE PHYSIOLOGY 
  Children with single ventricle physiology may develop 
ADHF following each one of the palliation stages. The initial 
management of these patients is similar in principal to the 
management of children with two-ventricle physiology with 
ADHF, and includes inotropic support and IV diuretics. Me-
chanical ventilation in children with ADHF following the 
Glenn and Fontan procedures may be problematic since it 
may increase their PVR, however, this consideration is offset 
by the need to minimize work of breathing and oxygen con-
sumption. Their TPG and PVR are assessed in the cardiac 
catheterization laboratory following a period of stabilization. 
While severe, fixed elevation of pulmonary vascular resis-
tance that would preclude heart transplantation are unlikely 
in patients with cavopulmonary connections, nonpulsatile 
pulmonary flow can be associated with mild to moderate 
elevations of pulmonary vascular resistance that can result in 
primary right heart graft failure after transplant. [81] Inhaled 
nitric oxide and other pulmonary vasodilators may be bene-
ficial in single ventricle patients with reactive pulmonary 
vascular bed [82, 83]. We have observed an association with 
aortopulmonary collaterals and elevation of pulmonary resis-
tance in single ventricle heart transplant candidates [81] and 
an aggressive strategy to identify and embolize these collat-
erals prior to transplant may be beneficial.  
  Experience with MCS in these patients other than ECMO 
is very limited. The literature reveals only sporadic case re-
ports describing long-term MCS in the context of single-
ventricle physiology [84-86]. With the current availability of 
the Berlin Heart, it is likely experience with support of single 
ventricle physiology in infancy, after the bidirectional Glenn 
shunt, and in the failing Fontan patient will accumulate rap-
idly to allow for an evaluation the efficacy of VAD therapy 
to decrease elevated pulmonary resistance in this unique pa-
tient population. 
SPECIAL CONSIDERATIONS 
  Patients with CHD associated with unequal distribution 
of pulmonary blood flow may develop pulmonary vascular 
remodeling in one lung whereas the second lung may have 
normal pulmonary vasculature or only minimal structural 
changes leading to PVR elevation amenable to medical 
treatment. Unequal pulmonary blood flow distribution can be 
found in patients with Tetralogy of Fallot and pulmonary 
atresia with major aortopulmonary collaterals. Another pos-
sible cause for pulmonary blood flow maldistribution is par-
tial pulmonary venous obstruction involving pulmonary ve-
nous egress of one lung. Heart transplantation has been suc-
cessfully performed in such patients [87]. Pre-transplantation 
embolization of aortopulmonary collaterals, or ligation of 
these collaterals during transplantation may decrease the risk 
of primary graft failure due to volume overload [88, 89]. 
Another subset of patients that deserve special attention is 
that of patients with hypoplastic left heart syndrome and 
intact atrial septum. In spite of minimal pulmonary blood 
flow in utero, this combination is associated with nonim-
mune fetal hydrops [90] and congenital pulmonary cystic 
lymphangiectasis [91] and may result in prenatal mortality. 
Of those surviving to term, an immediate atrial septostomy is 
required after delivery because of severe hypoxemia. Even if 
no significant end organ damage develops in the immediate 
postnatal period, the outcome of these infants is still guarded 
due to maldevelopment of the pulmonary vasculature. 
Rychik and colleagues [92] identified three types of intact 
atrial septum by echocardiography: 1) type A is consistent of 
large left atrium, thick prominent septum secundum with 
thin septum primum adherent to each other; 2) type B is con-
sistent of a small left atrium with thick, muscular atrial sep-
tum, and 3) type C that consists of a giant left atrium, thin 
atrial septum with severe mitral regurgitation. Lung tissue 
specimens were obtained from six patients. Most striking 
findings were in the type B patients. The lymphatics were 
severely dilated and the pulmonary veins were thick, dilated 
and “arterialized” with multiple elastic laminae noted. The 
pulmonary vascular pathology, especially in type B patients 
may preclude these patients from the single ventricle pallia-
tion pathway. The question is if orthotopic heart transplanta-
tion alone is sufficient or whether heart-lung transplantation 
is required. There is no clear-cut answer since outcome data 
are minimal. Preliminary investigations should include: 1) a 
cardiac catheterization to assess the degree of pulmonary 
venous obstruction and PVR as well as the reactivity of the 
pulmonary vascular bed to pulmonary vasodilators; 2) an 
open lung biopsy. Early listing for either heart transplanta-
tion or heart-lung transplantation in patients that are not 64    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Gazit and Canter 
amenable for the Norwood procedure may be helpful in ac-
cruing time on the list since waiting time may be very long.  
CONCLUSION 
  In patients with CHD and end-stage heart failure, pulmo-
nary remodeling caused by abnormal pulmonary blood flow 
profiles may result in severe pulmonary hypertension refrac-
tory to pulmonary vasodilators, also known as fixed pulmo-
nary hypertension. This entity is considered a contraindica-
tion to orthotopic heart transplantation [93]. This entity is 
encountered more frequently in transplant candidates with 
congenital heart disease. Even in congenital heart disease 
patients who show reversibility of pulmonary resistance and 
evidence of “acceptable” hemodynamics, the uncertainties 
often involved in the measurement of pulmonary resistance 
in congenital heart disease candidates may often lead to pri-
mary graft failure from right heart failure after transplant. 
Careful planning of heart transplant procedures in this sub-
group of patients in preparation for this complication is war-
ranted as are ongoing efforts to minimize pulmonary resis-
tance in these patients prior to transplant. 
  Until recently, the treatment of patients with heart failure 
and fixed PVR was limited almost exclusively to combined 
heart-lung transplantation. However, over the course of the 
last decade, the concept of reverse remodeling of the pulmo-
nary vasculature with hemodynamic unloading of the heart 
has been confirmed both in adults and children supported 
with ventricular assist devices. This option opens new treat-
ment options for these patients. The definition of “fixed” 
pulmonary hypertension refractory to pulmonary vasodilator 
treatment that would preclude heart transplant in the current 
era of pediatric VAD availability is evolving as these new 
technologies are applied to congenital heart disease patients.  
REFERENCES  
[1]  Kirk R, Edwards LB, Kucheryavaya AY, et al. The Registry of the 
International Society for Heart and Lung Transplantation: 
thirteenth official pediatric heart transplantation report-2010. J 
Heart Lung Transplant 2010; 29(10):1119-28. 
[2]  Lamour JM, Kanter KR, Naftel DC, et al. Cardiac Transplant 
Registry Database; Pediatric Heart Transplant Study. The effect of 
age, diagnosis, and previous surgery in children and adults 
undergoing heart transplantation for congenital heart disease. J Am 
Coll Cardiol 2009; 54: 160-5. 
[3]  Delgado JF, Gómez-Sánchez MA, Sáenz de la Calzada C, et al. 
Impact of mild pulmonary hypertension on mortality and 
pulmonary artery pressure profile after heart transplantation. J 
Heart Lung Transplant 2001; 20: 942-8. 
[4]  Hoskote A, Carter C, Rees P, Elliott M, Burch M, Brown K. Acute 
right ventricular failure after pediatric cardiac transplant: predictors 
and long-term outcome in current era of transplantation medicine. J 
Thorac Cardiovasc Surg 2010; 139(1): 146-53. 
[5]  Huang J, Trinkaus K, Huddleston CB, Mendeloff EN, pray TL, CE 
C. Risk factors for primary graft failure after pediatric cardiac 
transplantation: importance of recipient and donor characteristics. J 
Heart Lung Transplant 2004; 23(6): 716-22. 
[6]  Mitchell MB, Campbell DN, Ivy D, Boucek MM, Sondheimer HM, 
Pietra B, et al. Evidence of pulmonary vascular disease after heart 
transplantation for Fontan circulation failure. J Thorac Cardiovasc 
Surg 2004; 128(5): 693-702. 
[7]  Zakliczynski M, Zebik T, Maruszewski M, et al. Usefulness of 
pulmonary hypertension reversibility test with sodium nitroprusside 
in stratification of early death risk after orthotopic heart 
transplantation. Transplant Proc 2005; 37: 1346-8. 
[8]  Klotz S, eng MC, Hanafy D, et al. Reversible pulmonary 
hypertension in heart transplant candidates--pretransplant 
evaluation and outcome after orthotopic heart transplantation. Eur J 
Heart Fail 2003; 5(5): 645-53. 
[9]  Mahajan A, Shabanie A, Varshney SM, Marijic J, MJ S. Inhaled 
nitric oxide in the preoperative evaluation of pulmonary 
hypertension in heart transplant candidates. J Cardiothorac Vasc 
Anest 2007; 21(1): 51-6. 
[10]  Balzer DT, Kort HW, Day RW, et al. Inhaled Nitric Oxide as a 
Preoperative Test (INOP Test I): the INOP Test Study Group. 
Circulation. 2002; 106: I76-I81. 
[11]  Jabbour A, Keogh A, Hayward C, Macdonald P. Chronic sildenafil 
lowers transpulmonary gradient and improves cardiac output 
allowing successful heart transplantation. Eur J Heart Fail 2007; 
9(6-7): 674-7. 
[12]  Sansone F. Oral sildenafil: potential role in heart transplantation. 
Review of the literature and personal experience. J Cardiol 2010; 
55(3): 291-5. 
[13]  Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial 
effect of oral sildenafil therapy on childhood pulmonary arterial 
hypertension: twelve-month clinical trial of a single-drug, open-
label, pilot study. Circulation. 2005; 111(24): 3274-80. 
[14]  Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Effect of the 
oral endothelin antagonist bosentan on the clinical, exercise, and 
haemodynamic status of patients with pulmonary arterial 
hypertension related to congenital heart disease. Heart 2005; 91: 
1447-52. 
[15]  Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone 
in pre-transplant assessment of patients with congestive heart 
failure and pulmonary hypertension. J Heart Lung Transplant 1999; 
18(4): 367-71. 
[16]  Torres Macho J, Delgado Jimenez JF, Sanz Salvo J, et al. Effect of 
different pharmacologic agents to reverse severe pulmonary 
hypertension among end-stage heart failure patients. Transplant 
Proc 2009; 41(6): 2477-9. 
[17]  Dewey Jr. CF, Bussolari S, Gimbrone Jr. MA, et al. The dynamic 
response of vascular endothelial cells to fluid shear stress. J 
Biomech Eng 1981; 1-3: 177-85. 
[18]  Flaherty JT, Pierce JE, Ferrans VJ, et al. Endothelial nuclear 
patterns in the canine arterial tree with particular reference to 
hemodynamic events. Circ Res 1972; 30: 23-33. 
[19]  Langille BL, Adamson SL. Relationship between blood flow 
direction and endothelial cell orientation at arterial branch sites in 
rabbits and mice. Circ Res 1981; 48: 481-8. 
[20]  Levesque M, Liepsch D, Moravec S. Correlation of endothelial cell 
shape and wall shearstress in a stenosed dog aorta. Arteriosclerosis. 
1986; 6: 220-9. 
[21]  Okano M, Yoshida Y. Endothelial cell morphometry of 
atherosclerotic lesions and flow profiles at aortic bifurcations in 
cholesterol-fed rabbits. J Biomech Eng 1992; 114: 301-8. 
[22]  Okano M, Yoshida Y. Influence of shear stress on endothelial cell 
shapes and junction complexes at flow dividers of aortic 
bifurcations in cholesterol-fed rabbits. Front Med Biol Eng 1993; 5: 
95-120. 
[23]  Barbee KA, Davies PF, Lal R. Shear stress induced reorganization 
of the surface topography of living endothelial cells imaged by 
atomic force microscopy. Circ Res 1994; 74: 163-71. 
[24]  Traub O, Berk BC. Laminar shear stress: mechanisms by which 
endothelial cells transduce an atheroprotective force. Arterioscler. 
Thromb Vasc Biol 1998; 18: 677-85. 
[25]  Davies PF. Flow-mediated endothelial mechanotransduction. 
Physiol Rev 1995; 75: 519-60. 
[26]  Berthiaume F, Frangos JA. Fluid flow increases membrane 
permeability to merocyanine 540 in human endothelial cells. 
Biochim Biophys Acta 1994; 1191: 209-18. 
[27]  Kung CE, Reed JK. Microviscosity measurements of phospholipids 
bilayers using fluorescent dyes that undergo torsional relaxation. 
Biochemistry 1986; 25: 6114-21. 
[28]  Kapitulnik J, Weil E, Rabinowitz R, et al. Fetal and adult human 
liver differ markedly in the fluidity and lipid composition of their 
microsomal membranes. Hepatology. Hepatology 1987; 7: 55-60. 
[29]  Dunham WR, Sands RH, Klein SB, et al. EPR measurements 
showing that plasma membrane viscosity can vary from 30 to 100 
cP in human epidermal cell strains. Spectrochim Acta 1996; A52: 
1357-68. 
[30]  Cohen MH, Turnbull D. Molecular transport in liquids and glasses. 
J Chem Phys 1959; 31. Impact of Pulmonary Vascular Resistances in Heart Transplantation  Current Cardiology Reviews, 2011, Vol. 7, No. 2    65 
[31]  Doolittle AK. Studies in Newtonian flow. II. The dependence of 
the viscosity of liquids on free-space. J Appl Phys 1951; 22: 1471-
5. 
[32]  Haidekker M, L’Heureux N, Frangos JA. Fluid shear stress 
increases membrane fluidity in endothelial cells: a study with 
DCVJ fluorescence. Am J Physiol 2000; 278: H1401–H6. 
[33]  Haidekke M, White CR, L’Heureux N, et al. Analysis of temporal 
shear stress gradients during the onset phase of flow over a 
backward-facing step. Implications on endothelia cell proliferation. 
J Biomech Eng 2001; 123: 455-63. 
[34]  Gudi SRP, Nolan JP, Frangos JA. a Modulation of GTPase activity 
of G proteins by fluid shear stress and phospholipid composition. 
Proc Natl Acad Sci USA 1998; 95: 2515-9. 
[35]  Hanggi P, Talkner P, Borkovec M. Reaction-rate theory—50 years 
after Kramers. Rev Modern Phys 1990; 62: 251-341. 
[36]  Beece D, Eisenstein L, Frauenfelder H, et al. Solvent viscosity and 
protein dynamics. Biochemistry 1980; 19: 5147-57. 
[37]  Berthiaume F, Frangos JA. Flow-induced prostacyclin production 
is mediated by a pertussis toxinsensitive G-protein. FEBS Lett 
1992; 30: 277-9. 
[38]  Hsieh HJ, Li NQ, Frangos JA. Shear-induced platelet-derived 
growth factor gene expression in human endothelial cells is 
mediated by protein kinase-C. J Cell Physiol Rev 1992; 150: 552-8. 
[39]  Kuchan MJ, Jo H, Frangos JA. Role of G proteins in shear stress-
mediated nitric oxide production by endothelial cells. Am J Physiol 
1994; 267: C753–C8. 
[40]  Frangos JA, Huang TY, Clark CB. Steady shear and step changes 
in shear stimulate endothelium via independent mechanisms—
superposition of transient and sustained nitric oxide production. 
Biochem Biophys Res Commun 1996; 224: 660-5. 
[41]  Gudi SRP, Clark CB, Frangos JA. Fluid flow rapidly activates G 
proteins in human endothelial cells Circ Res 1996; 79: 834-9. 
[42]  White CR, Frangos JA. The shear stress of it all: the cell membrane 
and mechanochemical transduction Philos Trans R Soc Lond B 
Biol Sci 2007; 362: 1459-67. 
[43]  Storme L, Parker TA, Kinsella JP, et al. Chronic hypertension 
impairs flow-induced vasodilation and augments the myogenic 
response in fetal lung. Am J Physiol Lung Cell Mol Physiol 2002; 
2823: L56-L66. 
[44]  Ross GA, Oishi P, Azakie A, et al. Endothelial alterations during 
inhaled NO in lambs with pulmonary hypertension: implications 
for rebound hypertension. Am J Physiol Lung Cell Mol Physiol 
2005; 288: L27-L35. 
[45]  Rondelet B, Kerbaul F, Van Beneden R, et al. Prevention of 
pulmonary vascular remodeling and of decreased BMPR-2 
expression by losartan therapy in shunt-induced pulmonary 
hypertension. Am J Physiol Heart Circ Physiol 2005; 289: H2319-
H24. 
[46]  Steinhorn RH, Russell JA, Lakshminrusimha S, Gugino SF, Black 
SM, JR F. Altered endothelium-dependent relaxations in lambs 
with high pulmonary blood flow and pulmonary hypertension. Am 
J Physiol Heart Circ Physiol 2001; 280(1): H311-H7. 
[47]  Rabinovitch M, Konstam MA, Gamble WJ, et al. Changes in 
pulmonary blood flow affect vascular response to chronic hypoxia 
in rats. Circ Res 1983; 52(4): 432-41. 
[48]  Li M, Stenmark KR, Shandas R, Tan W.. Effects of pathological 
flow on pulmonary artery endothelial production of vasoactive 
mediators and growth factors. J Vasc Res 2009; 46(6): 561-71. 
[49]  Delgado JF, Conde E, Sánchez V, et al. Pulmonary vascular 
remodeling in pulmonary hypertension due to chronic heart failure. 
Eur J Heart Fail 2005; 7: 1011-6. 
[50]  Rabinovitch M, Haworth SG, Castaneda AR, et al. Lung biopsy in 
congenital heart disease: a morphometric approach to pulmonary 
vascular disease. Circulation 1978; 58: 1107-22. 
[51]  Rabinovitch M, Keane JF, Norwood WI, et al. Vascular structure in 
lung tissue obtained at biopsy correlated with pulmonary 
hemodynamic findings after repair of congenital heart defects. 
Circulation 1984; 69: 655-67. 
[52]  Heath D, Edwards JE. The pathology of hypertensive pulmonary 
vascular disease; a description of six grades of structural changes in 
the pulmonary arteries with special reference to congenital cardiac 
septal defects. Circulation 1958; 18: 533-47. 
[53]  Ross R, Glomset A, Kariya B, et al. A platelet dependent serum 
factor that stimulates the proliferation of arterial smooth muscle 
cells in vitro. Proc Natl Acad Sci 1974; 71: 1207. 
[54]  Meyrick B, Reid L. Ultrastructural findings in lung biopsy material 
from children with congenital heart defects. Am J Pathol 1980; 
101: 527. 
[55]  Fishman JA, Ryan FB, Karnovsky MJ. Endothelial regeneration in 
the rat carotid artery and the significance of endothelial denudation 
in the pathogenesis of myointimal thickening. Lab Invest 1975; 32: 
339. 
[56]  Harker LA, Ross R, Slichter SJ, et al. Homocystine-induced 
arteriosclerosis: the role of endothelial cell injury' and platelet 
responsein its genesis. J Clin Invest 1976; 5s: 731. 
[57]  Gajarski RJ, Towbin JA, Bricker JT, et al. Intermediate follow-up 
of pediatric heart transplant recipients with elevated pulmonary 
vascular resistance index. J Am Coll Cardiol 1994; 23: 1682-7. 
[58]  Deng MC, Gradaus R, Hammel D, et al. Heart transplant 
candidates at high risk can be identified at the time of initial 
evaluation. Transpl Int 1996; 9: 38-45. 
[59]  Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist 
devices decrease fixed pulmonary hypertension in cardiac 
transplant candidates. J Thorac Cardiovasc Surg 2007; 133: 689-95. 
[60]  Kaye MP. The Registry of the International Society for Heart and 
Lung Transplantation: ninth official report—1992. J Heart Lung 
Transplant 1992; 11: 599-606. 
[61]  Wang SS, Chu SH, Ko WJ, et al. Heterotopic heart transplantation 
for severe pulmonary hypertension. Transplant Proc 1998; 30: 
3408-9. 
[62]  Elefteriades JA, Lovoulos CJ, Tellides G, et al. Right ventricle-
sparing heart transplant: promising new technique for recipients 
with pulmonary hypertension. Ann Thorac Surg 2000; 69: 1858-63; 
discussion 63-4. 
[63]  Lovoulos C, Tittle S, Goldstein L, et al. Right ventricle-sparing 
heart transplantation effective against iatrogenic pulmonary 
hypertension. J Heart Lung Transplant 2004; 23: 236-41. 
[64]  Birks EJ, Yacoub MH, Anyanwu A, et al. Transplantation using 
hearts from primary pulmonary hypertensive donors for recipients 
with a high pulmonary vascular resistance. J Heart Lung Transplant 
2004; 23: 1339-44. 
[65]  O'Blenes SB, Fischer S, McIntyre B, et al. Hemodynamic 
unloading leads to regression of pulmonary vascular disease in rats. 
J Thorac Cardiovasc Surg 2001; 121: 279-89. 
[66]  Etz CD, Welp HA, Tjan TD, et al. Medically refractory pulmonary 
hypertension: treatment with nonpulsatile left ventricular assist 
devices. Ann Thorac Surg 2007; 83: 1697-709. 
[67]  Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist 
devices decrease fixed pulmonary hypertension in cardiac 
transplant candidates. J Thorac Cardiovasc Surg 2007; 133: 689-95. 
[68]  Gallagher RC, Kormos RL, Gasior T, et al. Univentricular support 
results in reduction of pulmonary resistance and improved right 
ventricular function. ASAIO Transplant 1991; 37: M287-M8. 
[69]  Smedira NG, Massad MG, Navia J, et al. Pulmonary hypertension 
is not a risk factor for RVAD use and death after left 
ventricularassist system support. ASAIO J 1996; 42: M733-M5. 
[70]  Baldovinos A, Kalangos A, Sierra J, et al. Is partially 
reversiblepulmonary hypertension a contraindication for heart 
transplantation? . Transplant Proc 2000; 32: 468-9. 
[71]  Petrofski JA, Hoopes CW, Bashore TM, et al. Mechanical 
ventricular support lowers pulmonary vascular resistance in a 
patient with congential heart diseas. Ann Thorac Surg 2003; 75: 
1005-7. 
[72]  Martin J, Siegenthaler MP, et al. Implantable left ventricular assist 
device for treatment of pulmonary hypertension in candidates for 
orthotopic heart transplantation—a preliminary study. Eur J 
Cardiothorac Surg 2004; 25: 971-7. 
[73]  Al-Khaldi A, Ergina P, DeVarennes B, et al. Left ventricular 
unloading in a patient with end-stage cardiomyopathy and 
medically unresponsive pulmonary hypertension. Artif Organs 
2004; 28: 158-60. 
[74]  Choong CK, Pasque MK, Shelton K, et al. The beneficial role of 
left ventricular assist device destination therapy in the reversal of 
contraindications to cardiac transplantation. J Thorac Cardiovasc 
Surg 2005; 130: 879-80. 
[75]  Haddad H, Elabbassi W, Moustafa S, et al. Left ventricular assist 
device as bridge to heart transplantation in congestive heart failure 
with pulmonary hypertension. ASAIO J 2005; 51: 456-60. 
[76]  Salzberg SP, Lachat ML, von Harbou K, et al. Normalization of 
high pulmonary vascular resistance with LVAD support in heart 66    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Gazit and Canter 
transplantation candidates. Eur J Cardiothorac Surg 2005; 27: 222-
5. 
[77]  Zimpfer D, Zrunek P, Sandner S, et al. Posttransplant survival after 
lowering fixed pulmonary hypertension using left ventricular assist 
devices. Eur J Cardiothorac Surg 2007; 31: 698-702. 
[78]  Gandhi SK, Grady RM, Huddleston CB, et al. Beyond Berlin: heart 
transplantation in the "untransplantable". J Thorac Cardiovasc Surg 
2008; 136: 529-31. 
[79]  Gandhi SK, Huddleston CB, Balzer DT, et al. Biventricular assist 
devices as a bridge to heart transplantation in small children. 
Circulation 2008; 118: S89-S93. 
[80]  Gazit AZ, Oren PP. Pharmaceutical management of decompensated 
heart failure syndrome in children: current state of the art and a 
new approach. Curr Treat Options Cardiovasc Med 2009; 11: 403-
9. 
[81]  K Simpson* a, C Canter, C Lee, et al. Failed Fontan Heart 
Transplant Candidates with Preserved Versus Impaired Ventricular 
Ejection: 2 Distinct Patient Populations. The Journal of Heart and 
Lung Transplantation 2011; 30: S167. 
[82]  Reinhardt Z, Uzun O, Bhole V, et al. Sildenafil in the management 
of the failing Fontan circulation. Cardiol Young 2010; 20: 522-5. 
[83]  Giardini A, Balduci A, Specchia S, et al. Effect of Sildenafil on 
haemodynamic response to exercise and exercise capacity in 
Fontan patients. Eur Heart J 2008; 29: 1681-7. 
[84]  Frazier OH, Gregoric ID, Messner GN. Total circulatory support 
with an LVAD in an adolescent with a previous Fontan procedure. 
Tex Heart Inst J 2005; 8(32): 402-4. 
[85]  Nathan M, Baird C, Fynn-Thompson F, et al. Successful 
implantation of a Berlin heart biventricular assist device in a failing 
single ventricle. J Thorac Cardiovasc Surg 2006; 131: 1407-8. 
[86]  Newcomb AE, Negri JC, Brizard CP, et al. Successful left 
ventricular assist device bridge to transplantation after failure of a 
fontan Fontan revision. J Heart Lung Transplant 2006; 25: 365-7. 
[87]  Chen JM, Davies RR, Mital SR, et al. Trends and outcomes in 
transplantation for complex congenital heart disease: 1984 to 2004. 
Ann Thorac Surg 2004; 78: 1352-61. 
[88]  Kanter KR, Vincent RN, Raviele AA. Importance of acquired 
systemic-to-pulmonary collaterals in the Fontan operation. Ann 
Thorac Surg. 1999; 68: 969-75. 
[89]  Krishnan US, Lamour DT, Hsu DT, et al. Management of 
aortopulmonary collaterals in children following cardiac 
transplantation for complex congenital heart disease J Heart Lung 
Transplant 2004; 23: 948-53. 
[90]  Pesonen E, Haavisto H, Ammala P, et al. Intrauterine hydrops 
caused by premature closure of the foramen ovale. Arch Dis Child 
1983; 58: 1015-6. 
[91]  Moerman PL, Van Dijck H, Lauweryns JM, et al. Premature 
closure of the foramen ovale and congenital pulmonary cystic 
lymphangiectasis in aortic valve atresia or in severe aortic valve 
stenosis. Am J Cardiol 1986; 57: 703-5. 
[92]  Rychik J, ome JJ, Collins MH, et al. The hypoplastic left heart 
syndrome with intact atrial septum: atrial morphology, pulmonary 
vascular histopathology and outcome. J Am Coll Cardiol 1999; 34: 
554-60. 
[93]  Canter CE, Shaddy RE, Bernstein D, et al. American Heart 
Association Council on Cardiovascular Disease in the Young; 
American Heart Association Council on Clinical Cardiology; 
American Heart Association Council on Cardiovascular Nursing; 
American Heart Association Council on Cardiovascular Surgery 
and Anesthesia; Quality of Care and Outcomes Research 
Interdisciplinary Working Group. Indications for heart 
transplantation in pediatric heart disease: a scientific statement 
from the American Heart Association Council on Cardiovascular 
Disease in the Young; the Councils on Clinical Cardiology, 
Cardiovascular Nursing, and Cardiovascular Surgery and 
Anesthesia; and the Quality of Care and Outcomes Research 
Interdisciplinary Working Group. Circulation 2007; 115: 658-76. 
 
 
Received: December 30, 2010  Revised: May 23, 2011             Accepted: June 27, 2011 
 
 
 